A phase I open-label, single-dose trial of methylphenidate extended- release (Cotempla XR-ODT) in children and adolescents with attention-deficit hyperactivity disorder

Trial Profile

A phase I open-label, single-dose trial of methylphenidate extended- release (Cotempla XR-ODT) in children and adolescents with attention-deficit hyperactivity disorder

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Nov 2015

At a glance

  • Drugs Methylphenidate (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Pharmacokinetics
  • Most Recent Events

    • 04 Nov 2015 New trial record
    • 30 Oct 2015 According to a Neos Therapeutics media release, results from this trial were presented at the American Academy of Child and Adolescent Psychiatry's (AACAP) 62nd Annual Meeting.
    • 30 Oct 2015 Results were published in a Neos Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top